AstraZeneca’s release Monday of encouraging data about its coronavirus vaccine from its U.S. trial raised hopes that the drug company could put a troubled rollout behind it. But just hours after its announcement, American officials issued an unusual statement expressing concern the company had included “outdated information” from its study and that it may have provided “an incomplete view of the efficacy data.”